The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine

Hills, Thomas; Paterson, Aimee; Woodward, Rebecca M; Middleton, F. M.; Carlton, Lauren H; McGregor, Reuben; Barfoot, Sebastien; Ramiah, Ciara; Whitcombe, Alana L; Zimbron, Victor M; Mahuika, David; Brown, Joshua; Palmer-Neels, Kate; Manning, Brittany; Jani, Devanshi; Reeves, Brooke; Whitta, Georgia T; Morpeth, Susan; Beasley, R. Palmer; Weatherall, Mark; Jordan, A. M.; McIntyre, Peter; Moreland, Nicole J.; Mirjalili, S. Ali

doi:10.1016/j.vaccine.2022.06.070

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventy-six studies were included in the qualitative analysis ( Table S2 ). Ten studies were conducted in Israel [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ], one study in Denmark [ 39 ], eight studies in Italy [ 8 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ], three studies in the USA [ 47 , 48 , 49 ], nine studies in Germany [ 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ], one study in New Zealand [ 59 ], three studies in Austria [ 60 , 61 , 62 ], four studies in Spain [ 63 , 64 , 65 , 66 ], one study in Japan [ 67 ], one study in France [ 68 ], one study in Romania [ 69 ], one study in Peru [ 70 ], one study in Canada [ 71 ], six studies in Brazil [ 72 , 73 , 74 , 75 ,…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies were conducted in Israel [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ], one study in Denmark [ 39 ], eight studies in Italy [ 8 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ], three studies in the USA [ 47 , 48 , 49 ], nine studies in Germany [ 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ], one study in New Zealand [ 59 ], three studies in Austria [ 60 , 61 , 62 ], four studies in Spain [ 63 , 64 , 65 , 66 ], one study in Japan [ 67 ], one study in France [ 68 ], one study in Romania [ 69 ], one study in Peru [ 70 ], one study in Canada [ 71 ], six studies in Brazil [ 72 , 73 , 74 , 75 , 76 , 77 ], two studies in China [ …”

Section: Resultsmentioning

confidence: 99%

“…All studies concerned adult participants (the majority of participants were >18 years of age), and only one study also involved pediatric participants [ 91 ]. Sixty-six studies included participants who had only had a primary dose vaccine [ 8 , 29 , 30 , 35 , 36 , 37 , 38 , 39 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 82 , 83 , 84 , 85 , …”

Section: Resultsmentioning

confidence: 99%

“…There were 54 studies reporting immunogenicity: 27 studies on mRNA vaccines (13 studies on Pfizer/BioNTech [ 30 , 31 , 34 , 36 , 38 , 39 , 43 , 46 , 54 , 59 , 61 , 67 , 68 ], 1 study on Moderna [ 101 ], and 13 studies on Pfizer/BioNTech or Moderna [ 8 , 35 , 41 , 44 , 47 , 50 , 51 , 52 , 53 , 60 , 62 , 65 , 71 ]); 9 studies on inactivated virus vaccines using CoronaVac [ 72 , 73 , 74 , 75 , 76 , 77 , 79 , 80 , 83 ]; 2 studies on adenovirus vector vaccines [ 84 , 87 ]; 12 studies on mRNA and adenovirus vector vaccines (5 studies on Pfizer/BioNTech, Moderna, Vaxzevria, or Janssen [ 55 , 57 , 66 , 95 , 98 ], 2 studies on Pfizer/BioNTech, Moderna, or Vaxzevria [ 56 , 58 ], 3 studies on Pfizer/BioNTech or Vaxzevria [ 91 , 92 , 93 …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

Widhani,

Hasibuan,

Rismawati

et al. 2023

Vaccines

View full text Add to dashboard Cite

Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

Widhani,

Hasibuan,

Rismawati

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…This study was assessed by the Health and Disability Ethics Committee, and additional consent was not required. Samples were tested for SARS-CoV-1 anti-S1 IgG (Euroimmun Quantivac) as described [7].…”

mentioning

confidence: 99%